E-ISSN 2602-3164
EJMI. 2024; 8(4): 260-268 | DOI: 10.14744/ejmi.2024.38549

Prognostic Factors in Extensive-Stage Small Cell Lung Cancer: An Evaluation of LIPI, mGPS, and PIV Scores

Irem Oner1, Mustafa Buyukkor1, Fatih Tay1, Muhammed Esad Durmuş2, Alper Turkel1, Necla Demir1, Necati Alkis1, Cengiz Karacin1
1Department of Medical Oncology, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital Ankara, Türkiye, 2Department of Internal Medicine, Dr. Abdurrahman Yurtaslan Ankara Oncology Research and Training Hospital Ankara, Türkiye

Objectives: This study investigated the prognostic significance of three systemic inflammation-based indices—the Lung Immune Prognostic Index (LIPI), the modified Glasgow Prognostic Score (mGPS), and the Pan-Immune-Inflammation Value (PIV)—in patients with extensive-stage small-cell lung cancer (ES-SCLC) receiving first-line platinum-based chemotherapy. Methods: This retrospective study included 135 ES-SCLC patients. LIPI, mGPS, and PIV were calculated from pretreatment laboratory data. Kaplan-Meier and Cox regression analyses were used to evaluate the association of these indices with progression-free survival (PFS) and overall survival (OS). Results: Patients with an LIPI score of 2 experienced significantly worse OS (p=0.002) and PFS (p=0.001) compared to those with a score of 0. No significant association was observed between mGPS or PIV and survival outcomes. Multivariate analysis identified LIPI, prophylactic cranial irradiation, and female sex as independent prognostic factors. A LIPI score two was associated with worse OS (HR: 2.18; p=0.016) and PFS (HR: 2.20; p=0.012), while PCI and female sex were favorable prognostic factors. Conclusion: LIPI is an independent prognostic factor for ES-SCLC patients receiving first-line platinum-based chemotherapy. Incorporating LIPI into clinical practice may improve risk stratification and guide personalized treatment strategies. Keywords: Small cell lung carcinoma; prognostic factors; lung immune prognostic index; modified glasgow prognostic score, pan-immune-inflammation value


Cite This Article

Oner I, Buyukkor M, Tay F, Durmuş M, Turkel A, Demir N, Alkis N, Karacin C. Prognostic Factors in Extensive-Stage Small Cell Lung Cancer: An Evaluation of LIPI, mGPS, and PIV Scores. EJMI. 2024; 8(4): 260-268

Corresponding Author: Irem Oner

Full Text PDF PDF Download
EJMI & EJMI